muscle loss on glp-1 Glucagon-like peptide-1 receptor agonists and mass effects GLP-1 receptor agonists and muscle

UCSF Magazine+2Wikipedia+2 Some rare but more serious risks are under investigation: possible issues with gallbladder disease, pancreatitis, or delayed gastric emptying

November 1, 2024: Physicians Warn People Taking Ozempic of Skeletal Muscle Mass Loss and Call for More Research Recent commentary published in JAMA warns that skeletal muscle mass (SMM) experienced while taking GLP-1 drugs may be of medical concern

In this analysis, the unadjusted comparison did not show a significant difference in all-cause mortality or recurrence-free survival between GLP-1 receptor agonists and SGLT2 inhibitors

doi:10.1016/S0021-9258(18)42531-8 59